



Cite this: *Chem. Sci.*, 2017, 8, 3905

Selective single molecule nanopore sensing of proteins using DNA aptamer-functionalised gold nanoparticles†

Xiaoyan Lin, Aleksandar P. Ivanov * and Joshua B. Edel *

Single molecule detection methods, such as nanopore sensors have found increasing importance in applications ranging from gaining a better understanding of biophysical processes to technology driven solutions such as DNA sequencing. However, challenges remain especially in relation to improving selectivity to probe specific targets or to alternatively enable detection of smaller molecules such as small-sized proteins with a sufficiently high signal-to-noise ratio. In this article, we propose a solution to these technological challenges by using DNA aptamer-modified gold nanoparticles (AuNPs) that act as a molecular carrier through the nanopore sensor. We show that this approach offers numerous advantages including: high levels of selectivity, efficient capture from a complex mixture, enhanced signal, minimized analyte-sensor surface interactions, and finally can be used to enhance the event detection rate. This is demonstrated by incorporating a lysozyme binding aptamer to a 5 nm AuNP carrier to selectively probe lysozyme within a cocktail of proteins. We show that nanopores can reveal sub-complex molecular information, by discriminating the AuNP from the protein analyte, indicating the potential use of this technology for single molecule analysis of different molecular analytes specifically bound to AuNP.

Received 26th January 2017
Accepted 14th March 2017

DOI: 10.1039/c7sc00415j

rsc.li/chemical-science

Introduction

Proteins are an essential part of living organisms and the ability to discriminate individual proteins in complex environments is crucial for modern chemical, biological research and medical diagnostics. Typical detection strategies include the use of mass spectroscopy¹ and enzyme-linked immunosorbent assays (ELISA).² However, these are bulk methods relying on ensemble averaging masking any rare events. To circumvent this problem, single molecule methods have been developed based on either optical or electrical readout.^{3,4}


One example of a single molecule platform is solid-state nanopore sensing.^{3,5-9} The operating principle is simple, in a typical experiment, biological molecules are electrophoretically or electro-osmotically driven (translocated) through a nanopore by an externally applied electric field, resulting in a temporal modulation of the measured ionic current.^{3,6} From these modulations one can extract information on molecular properties such as length, composition, and interactions with other biomolecules.^{3,10} Although DNA based analysis has been most commonly performed,¹¹⁻¹³ more recently there has been a growing interest in protein based nanopore sensing to

determine physical parameters such as size,^{9,14} conformational state,^{15,16} protein-protein interaction and binding kinetics between protein and antibodies/aptamers.¹⁷⁻²⁵ However, compared with DNA, proteins exhibit a diverse range of sizes, three-dimensional structures and have a non-uniform charge distribution, which introduces experimental challenges. This is particularly true for the detection of small protein molecules, due to their fast translocation through the nanopore detector and low event rates, resulting in the detection of only a small fraction of the proteins, even with high bandwidth electronics.^{26,27} Although thin and small solid-state nanopores (<10 nm) have been developed for the detection of small proteins, fabrication is complex.²⁸⁻³⁰ Furthermore, with decreasing protein size, signals become increasingly difficult to detect due to lowering of the signal-to-noise ratio.^{9,26} Perhaps the greatest challenge in protein nanopore detection, has been the lack of selectivity, where proteins of similar size cannot be differentiated. Specifically, it is exceptionally challenging to extract chemical information from a Coulter counter-like measurement without introducing a strategy to tackle selectivity.¹⁷ Low selectivity is a major obstacle in many single molecule methods and especially for nanopores in heterogeneous samples and/or biological fluids.

Incorporation of binding sites in solid-state nanopores to improve selectivity has been previously demonstrated, including anchoring nitrilotriacetic acid for stochastic sensing of His-tagged proteins,²² and encoding of aptamers on glass nanopores.¹⁹ However, nanopore functionalization requires

Department of Chemistry, Imperial College London, South Kensington, London SW7 2AZ, UK. E-mail: joshua.edel@imperial.ac.uk; alex.ivanov@imperial.ac.uk

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c7sc00415j



Open Access Article. Published on 20 Hlakuwe 2017. Downloaded on 2025-08-19 03:27:44.
This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence.

Single molecule detection with nanopipettes

A comparison between translocation characteristics of controls (*i.e.* AuNP, AuNP-LBA, lysozyme on its own) and the AuNP-LBA/lysozyme complex is shown in Fig. 2. It is noteworthy to point out that the PEG-modified AuNPs only showed translocation events with small current enhancement. As an example, this is shown in the current–time trace in Fig. 2A taken at an AuNP concentration of 4 nM and applied potential of -600 mV (patch electrode in the external bath and ground electrode inside the nanopipette) where the mean current amplitude was calculated to be 45 ± 2 pA. In comparison the AuNP-LBAs also exhibited current enhancement with a larger amplitude of 77 ± 6 pA at -600 mV and a KCl concentration of 100 mM, Fig. 2B. The change in current amplitude acted as a good indicator of the

successful attachment of LBA to the AuNP. The observed current enhancement is in agreement with previous studies where it has been shown that positive counterions loosely attached to the functional groups on the surface of the ANP resulted in current enhancement.^{53–55} Furthermore, the ionic strength of the solution plays a dominant role and has been documented to directly affect the polarity of translocation events.^{56–59} For example, it has been shown that for KCl concentrations between 10–300 mM, DNA translocation results in nanopore current enhancement.⁵⁷ Due to the large surface charge of quartz nanopipettes, at the electrolyte concentrations used, DNA acts as a charge carrier leading to temporary increase in nanopore conductance. Similarly, in this work, the PEG and negatively charged LBA functionalisation on the AuNP surface facilitated charge accumulation on the complex.

The translocation of 500 nM lysozyme occurred under a reversed bias due to the +8 charge at pH 7.4. Current blockades were observed with an amplitude of 41 ± 2 pA at 600 mV (Fig. 2D). In contrast, after the binding between 0.5 nM AuNP-LBA and 250 nM lysozyme, the AuNP-LBA/lysozyme complex gave rise to a new class of blocking events with large amplitude (70 ± 9 pA) at 600 mV (Fig. 2E). The signal-to-noise ratio⁶⁰ increased to 11.1 compared with that of free lysozyme (6.3) at the same voltage. UV-Vis spectra confirmed that there was no aggregation after the binding between AuNP-LBA and lysozyme (Fig. S4†). The choice of lysozyme concentration used was motivated by the K_d (30–600 nM)^{51,52,61} between LBA and lysozyme, since higher concentration of lysozyme was needed to reach the saturation point. This was comparable to previous study, where anti-digoxigenin was detected ($K_d = 3.5$ nM) and the signal was saturated at the concentration of 6 nM, approximately at concentration twice the value of K_d .²⁰ To confirm that current transients were caused by the translocation of the AuNP-LBA/lysozyme complex, control experiments were carried out with AuNP-LBA at positive applied bias (600 mV), which showed no detectable events (Fig. 2C). Importantly, this method enabled clear differentiation between AuNP, AuNP-LBA and the AuNP-LBA/lysozyme complex by current amplitudes ranging from current enhancement at negative voltages to blockade at positive voltages. The changing of current polarity from current enhancement to blockade was caused by reduced counterions and increased excluded volume of the AuNP-LBA/lysozyme complexes, both of which resulted in decreased conductance.^{56,57} Furthermore, control experiments were carried out with LBA + lysozyme, AuNP + lysozyme, respectively, which demonstrated small blocking events at 600 mV (Fig. S5†). Translocation of lysozyme binding with AuNPs functionalised with a greater number of aptamers per particle (average 2) exhibited longer dwell times and a broader distribution, (Fig. S6†). These significant differences between the current-time traces of AuNP-LBA/lysozyme complexes, AuNPs, AuNP-LBAs, free lysozyme, LBA + lysozyme, AuNP + lysozyme verified the successful discrimination of the AuNP-LBA/lysozyme complexes at single molecule level with improved current blockade.

For the AuNP-LBA/lysozyme complex with moderate charge, electroosmotic flow dominates the analyte transport in quartz




Fig. 2 Current–time traces of (A) AuNPs and (B) AuNP-LBA at -600 mV and (C) AuNP-LBA, (D) free lysozyme, and (E) AuNP-LBA/lysozyme complexes at 600 mV with 100 mM KCl. The baseline current was -1230 pA for (A) AuNPs and -1200 pA for (B) AuNP-LBA at -600 mV; 2200 pA for (D) free lysozyme and 2300 pA for (E) AuNP-LBA/lysozyme complexes at 600 mV. AuNPs and AuNP-LBA exhibited current enhancement at negative voltages (events reversed for easier interpretation) while free lysozyme and AuNP-LBA/lysozyme complexes exhibited current blockade at positive voltages. Representative individual events are shown on the right-hand side of each trace.

nanopores due to higher surface charge of quartz compared to silicon nitride.⁷ We have previously estimated the electroosmotic flow (approximately 20 fL s^{-1} at 500 mV applied bias) for nanopipettes with the same geometry and at the same electrolyte concentration.⁴⁰

The larger current signal of the AuNP-LBA/lysozyme complexes relative to free lysozyme at the same voltage can be attributed to the increase in the excluded volume, where the amplitude of the current change is related to the excluded volume of the electrolyte inside the pore.^{15,62} Free lysozyme in solution has a diameter of around 3 nm ³⁸ which results in a relatively small excluded volume and a small current blockade amplitude with a low signal-to-noise ratio. In comparison, for the AuNP-LBA/lysozyme complex: the 52-base LBA is 17 nm in length and 1.5 nm in width when it is fully stretched. After binding with lysozyme, the LBA turns into a folded structure, with an approximate diameter of $6\text{--}9 \text{ nm}$. With the addition of the 5 nm AuNP, the diameter of the whole AuNP-LBA/lysozyme complex can be estimated to be around 11 to 14 nm . The larger excluded volume of the AuNP-LBA/lysozyme complexes led to a larger current blockade with a higher signal-to-noise ratio of 11.1 , which was substantially easier to detect in a nanopore experiment.

The efficient detection of smaller proteins is often hindered by low event frequency, fast translocation times, and small excluded volume.²⁶ Previous studies have revealed that the rate of detection for proteins is largely discrepant with predictions from the Smoluchowski rate equation ($J = 2\pi cDr_p$),²⁶ with up to 5 orders of magnitude difference for small proteins less than $\sim 20 \text{ kDa}$, such as lysozyme (14 kDa). Often what is being detected are translocation events on the tail end of the dwell time distribution (*i.e.* slower events) whereas most go undetected. Furthermore, the signal of the current blockade or enhancement is often small resulting in a low signal-to-noise ratio. For these reasons the detection of small-sized proteins often requires concentrations significantly higher compared to ones used in the detection of larger proteins.

Strategies have been used to enhance event rates, which include the utilization of high salt gradients,⁶³ high viscosity buffers,⁶⁴ pressure gradients,⁶⁵ temperature control⁶⁶ and dielectrophoretic trapping at the nanopore opening.³⁹ However, most of these studies focused on DNA and when applied to proteins, further experimental challenges could be introduced such as analyte aggregation and denaturation. A unique feature of this work is that the AuNP-LBA acts as a carrier, avoiding such experimental complications, while resulting in a 3.8 -fold improvement in the detection rates, Fig. 3B. For example, lysozyme's event frequency was 0.9 ± 0.1 events per s at a concentration of 250 nM . Whilst the event frequency for the AuNP-LBA/lysozyme complex increased to 3.6 ± 0.8 events per s at the same concentration, which was around 100 times of that of ubiquitin at a higher concentration using thin and small solid-state nanopores.³⁰ As discussed previously, the larger excluded volume of the AuNP-LBA/lysozyme complex led to an increased signal-to-noise ratio of 11.1 . At the same time, the decrease in the overall charge of the AuNP-LBA/lysozyme complex enabled further slowing down of individual




Fig. 3 (A) Schematic demonstrating the enhanced detection rate for the AuNP-LBA/lysozyme complex in comparison to that of free lysozyme. (B) The event rate of the AuNP-LBA/lysozyme complex resulted in a 3.8 -fold increase in comparison to free lysozyme. (C) Current blockade histogram for the AuNP-LBA/lysozyme complex at applied voltages of 300 mV (grey), 400 mV (orange), 500 mV (blue), 600 mV (green). (D) Mean current blockade of the AuNP-LBA/lysozyme complex as a function of voltage. (E) Dwell time histogram for the AuNP-LBA/lysozyme complex at applied voltages of 300 mV (grey), 400 mV (orange), 500 mV (blue), 600 mV (green). (F) Mean dwell time of the AuNP-LBA/lysozyme complex as a function of voltage, exhibiting a decreasing trend with increasing voltages.

translocations and resulted in improved detection. The combination of increased signal and lower translocation times contributed to the enhanced event rate. The K_d for lysozyme and LBA was $30\text{--}600 \text{ nM}$ according to previous reports.^{51,52} Thus, different concentrations of lysozyme, 50 nM , 100 nM , 200 nM , 250 nM were used in the translocation experiment. The event rate increased from 0.8 ± 0.1 events per s at 50 nM to 3.6 ± 0.8 events per s at 250 nM , showing a linear increasing in event rate with the increase of lysozyme concentration (Fig. 3B). The translocation of the AuNP-LBA/lysozyme complexes at different voltages were further studied, showing measurable current blockades at 300 mV – 600 mV (100 mV increment). The results verified the binding between LBA and lysozyme was stable even at higher voltages. Voltage-mediated unfolding of proteins has been reported,¹⁵ however such phenomenon was not observed in our studies due to the high binding affinity between LBA and lysozyme. The current blockade distribution (Fig. 3C) and mean peak amplitudes (Fig. 3D), rose from $32.9 \pm 0.6 \text{ pA}$ at 300 mV to $69.6 \pm 9.5 \text{ pA}$ at 600 mV and the mean dwell time decreased from $0.38 \pm 0.03 \text{ ms}$ to $0.32 \pm 0.05 \text{ ms}$ for the same voltages (Fig. 3E and F). Control current–voltage curves were recorded before and after the measurement (Fig. S7†), showing negligible current variation, indicating that there was minimal of any analyte adsorption to the nanopore surface.



A significant advantage of using aptamers for the detection of proteins with nanopores is in the high binding specificity between the aptamer and its target protein, making the method ideal for sensing in complex mixtures, Fig. 4A. To demonstrate the selectivity of our sensing approach, proteins with similar molecular weight and isoelectric point to lysozyme were used including cytochrome C (MW 12.4 kDa, pI 10.5) and trypsin (MW 23.3 kDa, pI 10.1). First, control experiments were carried out with lysozyme, cytochrome C and trypsin incubated with AuNP-LBAs individually and translocation studies were performed at a concentration of 250 nM and pH = 7.4. Translocation experiments revealed that only lysozyme gave rise to measurable current blockades (Fig. 4B(i)), while no translocations were observed for cytochrome C or trypsin (Fig. 4B(ii) and (iii)), confirming the specific binding of lysozyme to the AuNP-LBA. A comparison with the current-time trace of free lysozyme (Fig. 2D) verified that the events in Fig. 4B(i) were

produced by AuNP-LBA/lysozyme complexes rather than free lysozyme. The selectivity was further validated by analysing complex mixtures and varying concentrations (250 nM and 125 nM) as shown in Fig. 4B(iv) and (v). The event rate of the AuNP-LBA in mixed protein population was calculated to be 3.1 ± 0.3 events per s (Fig. 4B(iv)), consistent with that of AuNP-LBA/lysozyme in Fig. 4B(i) (3.2 ± 0.6 events per s), verifying that the AuNP-LBA was able to bind lysozyme specifically in the mixed population without interference from other proteins. With the concentration of lysozyme reduced to 125 nM, the event rate proportionally decreased to 1.1 ± 0.2 events per s (Fig. 4B(v)). Scatter plots of the current blockade against dwell time for AuNP-LBA/lysozyme (Fig. 4C) and AuNP-LBA in mixed protein population (Fig. 4D) demonstrated that the translocation events in both cases had similar current blockade and dwell time distribution, further confirming the applicability of the method to selectively sense lysozyme in protein mixture.

To elucidate sub-complex molecular information, a high bandwidth amplifier was used (VC 100 Chimera Amplifier, sampling at 1 MHz, with digital filtering at 30–100 kHz) to discriminate between the ionic current signatures of individual components of the AuNP-LBA/lysozyme complexes and to better understand the interaction between AuNP, LBA and lysozyme. Interestingly, distinctive two levels of current blockade were observed: a low current amplitude level was defined as “level 1” and a larger amplitude one, defined as “level 2” (Fig. 5A). At positive voltages, only the AuNP-LBA/lysozyme complexes (not AuNPs or AuNP-LBAs) translocated through the nanopipette and gave rise to such large current blockade. As the amplitude of current change is related to the excluded volume of the molecule that migrates through the nanopore, “level 1” is attributed to the small sized AuNPs, in accordance to the ionic signatures observed in control experiments, while “level 2” was due to the larger LBA/lysozyme complexes, Fig. 5A. The events with dwell time within 0.20–0.45 ms were further analysed and the results showed that ~65% of the events were in orientation i, while ~35% were in orientation ii, indicating that a larger proportion of the AuNP-LBA/lysozyme complexes tend to translocate with the AuNP passing firstly through the nanopore, and LBA/lysozyme coming after. These observations can potentially be explained by recent findings from Yusko *et al.* suggest that proteins with a dipole moment do not rotate and orient randomly under the influence of a high electric fields inside a nanopore.⁶⁷ Analogues to these findings, the LBA/lysozyme complex also has an inherent dipole moment and likely explains the observed preference in orientation in Fig. 5. Current blockade, dwell time, and equivalent charge distributions (the integrated current area over time) are shown in Fig. 5B and D and Fig. 5C and E for level 1 (AuNP) and level 2 (LBA/lysozyme complex), respectively. The mean current blockade for level 1 (AuNP) and level 2 (LBA/lysozyme complex) was 40 ± 11 pA and 76 ± 5 pA, mean dwell time was 0.10 ± 0.03 ms and 0.22 ± 0.07 ms, and finally the mean charge was 3 ± 1 fAs and 11 ± 4 fAs, respectively. The current blockade, charge




Fig. 4 (A) Scheme highlighting the selective single molecule detection of lysozyme in a complex mixture using AuNP-LBAs; (B) the current-time traces of the translocation of (i) AuNP-LBAs with lysozyme, (ii) AuNP-LBAs with cytochrome C, (iii) AuNP-LBAs with trypsin, (iv) AuNP-LBAs with lysozyme + cytochrome C + trypsin, (v) AuNP-LBAs with lysozyme + cytochrome C + trypsin at 600 mV. The X-ray structures of lysozyme, cytochrome C and trypsin are from PDB; scatter plots of the current blockade *versus* dwell time for the AuNP-LBA/lysozyme (C) and the AuNP-LBA in mixed protein population (D) showing similar distributions of current blockade and dwell time.




Fig. 5 (A) The two orientations of translocation events caused by the AuNP-LBA/lysozyme complex with two different levels of current blockade caused by AuNP (level 1) and LBA/lysozyme complex (level 2) at 400 mV, respectively. The probability for orientation i and ii was 0.65 and 0.35, respectively; heat plots of current blockade against dwell time for level 1 (B) and level 2 (C) with the distribution histograms of current blockade and dwell time on the sides; heat plots of charge against dwell time for level 1 (D) and level 2 (E) with the distribution histograms of charge and dwell time on the sides.

and dwell time of level 1 and level 2 were consistent with the size and charge of AuNPs and LBA/lysozyme complex. Perhaps most importantly, the results revealed that the AuNP and LBA/lysozyme can be used to distinguish the individual components relative to the whole complex. This is highly advantageous for applications where further multiplexing can be imagined. For example, it would be possible to distinguish between different analytes bound to an AuNP consisting of multiple aptamer sequences simply by interpreting the current blockade and dwell time.

Conclusions

In recent years there has been a substantial progress in the selection and optimisation of aptamers to target specific type of protein or even distinguish between protein isoforms or even to use aptamers as therapeutic agents. In most of the cases, however aptamers target specific proteins in heterogeneous samples, where potential protein biomarkers are often very small fraction of the total protein concentration. It is vital that sensing technologies capable of single molecule detection and discrimination are developed in conjunction with advances in

aptamer chemistry. Although this work focuses on technology development, it provides a strategy that enables selective protein detection that is potentially independent of the type of the aptamer used.

To demonstrate the feasibility, LBA has been successfully functionalised on the surface of AuNPs and bound at ratios of 1 : 2. This enabled the detection of lysozyme at the single molecule level by use of nanopore sensing. AuNP-LBAs acted as a carrier enabling more efficient detection of the protein. For example, the larger size and lower charge of the AuNP-LBA/lysozyme complex relative to free lysozyme resulted in larger current blockades and higher event capture rates. The AuNP-LBA/lysozyme complex also reduced the interaction between the negatively charged nanopipette and positively charged lysozyme. The high binding affinity between LBA and lysozyme resulted in the complex being stable at voltages up to 600 mV. It was also possible to discriminate between signal arising from the AuNP and signal arising from LBA/lysozyme binding using a high bandwidth amplifier, establishing the applicability of this method for single molecule detection of proteins in different chemical and biological conditions. This opens the door to the possibility in using this technology to differentiate between different molecular analytes bound to the AuNP (*e.g.* having multiple aptamers bound the AuNP targeting different proteins).


Due to the high specificity between LBA and lysozyme, the platform exhibited excellent selectivity to discriminate lysozyme from proteins with similar size and charge (as shown with trypsin and cytochrome C). We show that it was possible to detect lysozyme within a complex mixture with no false positives. More typically selectivity is often achieved when using nanopores by functionalising the surface with receptors or alternatively *via* use of another carrier molecule such as DNA. However, both these methods are either labour intensive or alternatively are not economically viable. Use of AuNPs not only facilitates detection, it is also easy to modify the functionality simply by using single pot thiol-Au chemistry. AuNPs are potential delivery system for therapeutic agents, showing good biocompatibility and low toxicity. Therefore, aptamer-functionalised AuNPs can find promising applications in medical and clinical areas.

Acknowledgements

J. B. E. has been funded in part by an ERC starting and consolidator investigator grant. J. B. E. and A. I. acknowledge receipt of an EPSRC grant. A. I. is funded by an Imperial College Fellowship and X. L. by Imperial College President's PhD Scholarship.

References

- 1 J. B. Fenn, M. Mann, C. K. Meng, S. F. Wong and C. M. Whitehouse, *Science*, 1989, **246**, 64–71.
- 2 E. Engvall and P. Perlmann, *Immunochemistry*, 1971, **8**, 871–874.



- 3 B. N. Miles, A. P. Ivanov, K. A. Wilson, F. Dogan, D. Japrun and J. B. Edel, *Chem. Soc. Rev.*, 2013, **42**, 15–28.
- 4 W. H. Pitchford, H. J. Kim, A. P. Ivanov, H. M. Kim, J. S. Yu, R. J. Leatherbarrow, T. Albrecht, K. B. Kim and J. B. Edel, *ACS Nano*, 2015, **9**, 1740–1748.
- 5 C. Dekker, *Nat. Nanotechnol.*, 2007, **2**, 209–215.
- 6 S. Howorka and Z. Siwy, *Chem. Soc. Rev.*, 2009, **38**, 2360–2384.
- 7 M. Firnkjes, D. Pedone, J. Knezevic, M. Dobliger and U. Rant, *Nano Lett.*, 2010, **10**, 2162–2167.
- 8 D. Fologea, B. Ledden, D. S. McNabb and J. Li, *Appl. Phys. Lett.*, 2007, **91**, 539011–539013.
- 9 W. Li, N. A. Bell, S. Hernandez-Ainsa, V. V. Thacker, A. M. Thackray, R. Bujdosó and U. F. Keyser, *ACS Nano*, 2013, **7**, 4129–4134.
- 10 H. Bayley and C. R. Martin, *Chem. Rev.*, 2000, **100**, 2575–2594.
- 11 H. Chang, F. Kosari, G. Andreadakis, M. A. Alam, G. Vasmatzis and R. Bashir, *Nano Lett.*, 2004, **4**, 1551–1556.
- 12 J. L. Li, M. Gershow, D. Stein, E. Brandin and J. A. Golovchenko, *Nat. Mater.*, 2003, **2**, 611–615.
- 13 R. P. Johnson, A. M. Fleming, L. R. Beuth, C. J. Burrows and H. S. White, *J. Am. Chem. Soc.*, 2016, **138**, 594–603.
- 14 L. J. Steinbock, S. Krishnan, R. D. Bulushev, S. Borgeaud, M. Blokesch, L. Feletti and A. Radenovic, *Nanoscale*, 2014, **6**, 14380–14387.
- 15 K. J. Freedman, S. R. Haq, J. B. Edel, P. Jemth and M. J. Kim, *Sci. Rep.*, 2013, **3**, 1638.
- 16 D. S. Talaga and J. Li, *J. Am. Chem. Soc.*, 2009, **131**, 9287–9297.
- 17 N. A. W. Bell and U. F. Keyser, *J. Am. Chem. Soc.*, 2015, **137**, 2035–2041.
- 18 N. A. W. Bell and U. F. Keyser, *Nat. Nanotechnol.*, 2016, **11**, 645–652.
- 19 S. Ding, C. Gao and L. Q. Gu, *Anal. Chem.*, 2009, **81**, 6649–6655.
- 20 J. L. Kong, N. A. W. Bell and U. F. Keyser, *Nano Lett.*, 2016, **16**, 3557–3562.
- 21 D. Rotem, L. Jayasinghe, M. Salichou and H. Bayley, *J. Am. Chem. Soc.*, 2012, **134**, 2781–2787.
- 22 R. Wei, V. Gatterdam, R. Wieneke, R. Tampe and U. Rant, *Nat. Nanotechnol.*, 2012, **7**, 257–263.
- 23 E. C. Yusko, J. M. Johnson, S. Majd, P. Prangkio, R. C. Rollings, J. L. Li, J. Yang and M. Mayer, *Nat. Nanotechnol.*, 2011, **6**, 253–260.
- 24 O. A. Saleh and L. L. Sohn, *Proc. Natl. Acad. Sci. U. S. A.*, 2003, **100**, 820–824.
- 25 J. D. Uram, K. Ke, A. J. Hunt and M. Mayer, *Small*, 2006, **2**, 967–972.
- 26 C. Plesa, S. W. Kowalczyk, R. Zinsmeister, A. Y. Grosberg, Y. Rabin and C. Dekker, *Nano Lett.*, 2013, **13**, 3445–3445.
- 27 J. Larkin, R. Y. Henley, M. Muthukumar, J. K. Rosenstein and M. Wanunu, *Biophys. J.*, 2014, **106**, 696–704.
- 28 N. Di Fiori, A. Squires, D. Bar, T. Gilboa, T. D. Moustakas and A. Meller, *Nat. Nanotechnol.*, 2013, **8**, 946–951.
- 29 D. J. Niedzwiecki, C. J. Land, G. Shemer, P. S. Cheng, J. G. Seven and M. Drndic, *ACS Nano*, 2015, **9**, 8907–8915.
- 30 I. Nir, D. Huttner and A. Meller, *Biophys. J.*, 2015, **108**, 2340–2349.
- 31 A. D. Ellington and J. W. Szostak, *Nature*, 1990, **346**, 818–822.
- 32 J. Liu, Z. Cao and Y. Lu, *Chem. Rev.*, 2009, **109**, 1948–1998.
- 33 D. L. Robertson and G. F. Joyce, *Nature*, 1990, **344**, 467–468.
- 34 C. Tuerk and L. Gold, *Science*, 1990, **249**, 505–510.
- 35 D. H. Bunka and P. G. Stockley, *Nat. Rev. Microbiol.*, 2006, **4**, 588–596.
- 36 C. K. O'Sullivan, *Anal. Bioanal. Chem.*, 2002, **372**, 44–48.
- 37 S. K. Verma, A. Amoah, U. Schellhaas, M. Winterhalter, S. Springer and T. A. Kolesnikova, *Adv. Funct. Mater.*, 2016, **26**, 6015–6024.
- 38 C. C. Blake, D. F. Koenig, G. A. Mair, A. C. North, D. C. Phillips and V. R. Sarma, *Nature*, 1965, **206**, 757–761.
- 39 K. J. Freedman, L. M. Otto, A. P. Ivanov, A. Barik, S. H. Oh and J. B. Edel, *Nat. Commun.*, 2016, **7**, 10217.
- 40 A. P. Ivanov, P. Actis, P. Jonsson, D. Klenerman, Y. Korchev and J. B. Edel, *ACS Nano*, 2015, **9**, 3587–3595.
- 41 J. Y. Y. Sze, S. Kumar, A. P. Ivanov, S. H. Oh and J. B. Edel, *Analyst*, 2015, **140**, 4828–4834.
- 42 P. Actis, A. C. Mak and N. Pourmand, *Bioanal. Rev.*, 2010, **1**, 177–185.
- 43 N. A. Bell, V. V. Thacker, S. Hernandez-Ainsa, M. E. Fuentes-Perez, F. Moreno-Herrero, T. Liedl and U. F. Keyser, *Lab Chip*, 2013, **13**, 1859–1862.
- 44 R. A. Levis and J. L. Rae, *Biophys. J.*, 1993, **65**, 1666–1677.
- 45 L. J. Steinbock, R. D. Bulushev, S. Krishnan, C. Raillon and A. Radenovic, *ACS Nano*, 2013, **7**, 11255–11262.
- 46 L. J. Steinbock, O. Otto, C. Chimere, J. Gornall and U. F. Keyser, *Nano Lett.*, 2010, **10**, 2493–2497.
- 47 R. J. White, E. N. Ervin, T. Yang, X. Chen, S. Daniel, P. S. Cremer and H. S. White, *J. Am. Chem. Soc.*, 2007, **129**, 11766–11775.
- 48 R. Elghanian, J. J. Storhoff, R. C. Mucic, R. L. Letsinger and C. A. Mirkin, *Science*, 1997, **277**, 1078–1081.
- 49 S. J. Hurst, A. K. Lytton-Jean and C. A. Mirkin, *Anal. Chem.*, 2006, **78**, 8313–8318.
- 50 J. X. Li, B. Q. Zhu, X. J. Yao, Y. C. Zhang, Z. Zhu, S. Tu, S. S. Jia, R. D. Liu, H. Z. Kang and C. J. Yang, *ACS Appl. Mater. Interfaces*, 2014, **6**, 16800–16807.
- 51 A. K. Cheng, B. Ge and H. Z. Yu, *Anal. Chem.*, 2007, **79**, 5158–5164.
- 52 J. C. Cox and A. D. Ellington, *Bioorg. Med. Chem.*, 2001, **9**, 2525–2531.
- 53 H. Cai, Y. Wang, Y. Yu, M. V. Mirkin, S. Bhakta, G. W. Bishop, A. A. Joshi and J. F. Rusling, *Anal. Chem.*, 2015, **87**, 6403–6410.
- 54 G. Goyal, K. J. Freedman and M. J. Kim, *Anal. Chem.*, 2013, **85**, 8180–8187.
- 55 Y. X. Wang, K. Kececi, M. V. Mirkin, V. Mani, N. Sardesai and J. F. Rusling, *Chem. Sci.*, 2013, **4**, 655–663.
- 56 R. M. M. Smeets, U. F. Keyser, D. Krapf, M. Y. Wu, N. H. Dekker and C. Dekker, *Nano Lett.*, 2006, **6**, 89–95.
- 57 L. J. Steinbock, A. Lucas, O. Otto and U. F. Keyser, *Electrophoresis*, 2012, **33**, 3480–3487.
- 58 W. J. Lan, C. Kubeil, J. W. Xiong, A. Bund and H. S. White, *J. Phys. Chem. C*, 2014, **118**, 2726–2734.



- 59 Y. Qiu, C. Yang, P. Hinkle, I. V. Vlassiouk and Z. S. Siwy, *Anal. Chem.*, 2015, **87**, 8517–8523.
- 60 R. M. M. Smeets, U. F. Keyser, N. H. Dekker and C. Dekker, *Proc. Natl. Acad. Sci. U. S. A.*, 2008, **105**, 417–421.
- 61 R. Kirby, E. J. Cho, B. Gehrke, T. Bayer, Y. S. Park, D. P. Neikirk, J. T. McDevitt and A. D. Ellington, *Anal. Chem.*, 2004, **76**, 4066–4075.
- 62 A. Oukhaled, B. Cressiot, L. Bacri, M. Pastoriza-Gallego, J. M. Betton, E. Bourhis, R. Jede, J. Gierak, L. Auvray and J. Pelta, *ACS Nano*, 2011, **5**, 3628–3638.
- 63 M. Wanunu, W. Morrison, Y. Rabin, A. Y. Grosberg and A. Meller, *Nat. Nanotechnol.*, 2010, **5**, 160–165.
- 64 D. Fologea, J. Uplinger, B. Thomas, D. S. McNabb and J. L. Li, *Nano Lett.*, 2005, **5**, 1734–1737.
- 65 B. Lu, D. P. Hoogerheide, Q. Zhao, H. Zhang, Z. Tang, D. Yu and J. A. Golovchenko, *Nano Lett.*, 2013, **13**, 3048–3052.
- 66 K. R. Mahendran, C. Chimerele, T. Mach and M. Winterhalter, *Eur. Biophys. J.*, 2009, **38**, 1141–1145.
- 67 E. C. Yusko, B. R. Bruhn, O. M. Eggenberger, J. Houghtaling, R. C. Rollings, N. C. Walsh, S. Nandivada, M. Pindrus, A. R. Hall, D. Sept, J. Li, D. S. Kalonia and M. Mayer, *Nat. Nanotechnol.*, 2016, DOI: 10.1038/nnano.2016.267.

